July 31, 2025

NADHJA – Development of a miniaturized measurement system for non-invasive detection of the acute individual metabolic state using artificial intelligence

NADHJA – Development of a miniaturized measurement system for non-invasive detection of the acute individual metabolic state using artificial intelligence

Lactate diagnostics is particularly important in sports medicine performance diagnostics and has been carried out conventionally for almost 100 years using blood samples and laboratory analyses.

This project aims to develop a measurement method and functional model of a mobile device based on the NADHJA analyzer from mfd Diagnostics GmbH, which uses a fluorescence-optical method and artificial intelligence (AI) to non-invasively determine changes in the concentration of the intracellular coenzyme NADH. The aim is to prove that these NADH changes correlate both with the accumulation of lactate at the site of measurement and with the systemic lactate change.

For the first time such a device would revolutionize lactate diagnostics in sports practice and open up the possibility of measuring lactate concentration non-invasively and continuously in real time. Biological waste is completely avoided. The development could also analyze atypical metabolic conditions, such as those that occur in fatigue syndrome, sepsis and long COVID, and thus enable new therapeutic approaches.

We are looking forward to this exciting joint project with the project partners of the Karlsruhe Institute of Technology (KIT), the Institute for Information Processing Technology (ITIV), the Institute for Sport and Sports Science (IfSS) and the Mannheim Institute for intelligent Systems in Medicine (MIISM) of the University Medical Center Mannheim (UMM). We would like to thank the performance diagnostics department of TSG 1899 Hoffenheim for their valuable support.

The project is supported by our location in Mannheim and funded by the state of Baden-Württemberg through the investBW program. We would like to thank the state of Baden-Württemberg for funding this project.

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp